Rocchi P, Ferreri A M, Simone G, Bagnara G P, Paolucci G
Centro Interdipartimentale di Ricerche sul Cancro Giorgio Prodi, Università di Bologna, Italy.
Anticancer Res. 1991 Sep-Oct;11(5):1885-9.
The antineoplastic drug 4'-iodo-4'-deoxydoxorubicin (IDX), a new halogenated anthracycline (1), was examined as a differentiation inducing agent on the human neuroblastoma cell lines TS12 and SK-N-MC. IDX induced morphological and biochemical differentiation and growth inhibition. The effect of a combined treatment of IDX with retinoic acid (RA) and with nerve growth factor (NGF) respectively was then investigated. The responses of neuroblastoma cells to IDX alone and to these combined treatments were compared, with respect to neuritic outgrowth, acetylcholinesterase activity and cellular growth. The data obtained indicate that the combination of differentiation-inducing drugs may be able to enhance the effects of the same drugs given alone.
抗肿瘤药物4'-碘-4'-脱氧阿霉素（IDX）是一种新型卤代蒽环类药物（1），被作为人神经母细胞瘤细胞系TS12和SK-N-MC的分化诱导剂进行了研究。IDX诱导了形态学和生化分化以及生长抑制。随后分别研究了IDX与视黄酸（RA）和神经生长因子（NGF）联合治疗的效果。比较了神经母细胞瘤细胞对单独使用IDX以及这些联合治疗的反应，涉及神经突生长、乙酰胆碱酯酶活性和细胞生长。所获得的数据表明，分化诱导药物的联合使用可能能够增强单独使用相同药物的效果。
